Market news

Detailed price information for Sensus Healthcare Inc (SRTS-Q) from The Globe and Mail including charting and trades.

Company secures delayed orders and sees growing international demand, positioning for a stronger second half.

Moby summary of Sensus Healthcare, Inc.'s Q2 2026 earnings call

Sensus Healthcare (NASDAQ:SRTS) reported second-quarter revenue of $2.3 million, down from $7.3 million a year earlier, as delayed third-party financing prevented the company from recognizing revenue tied to eight equipment units before the end of June. Chairman and Chief Executive Officer Joe Sard

BOCA RATON, Fla., August 13, 2026--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company committed to providing highly effective, non-invasive treatments for oncological and non-oncological skin conditions, today announced financial results and business highlights for the three months ended June 30, 2026.

BOCA RATON, Fla., July 30, 2026--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company committed to providing highly effective, non-invasive treatments for oncological and non-oncological skin conditions, today announced the company will report financial results for the second quarter of 2026 on Thursday, August 13, 2026. Management will hold a conference call beginning at 4:30 pm Eastern time to review the results, provide a business update and answer questions.